Baillie Gifford & CO Guardant Health, Inc. Transaction History
Baillie Gifford & CO
- $111 Billion
- Q1 2025
A detailed history of Baillie Gifford & CO transactions in Guardant Health, Inc. stock. As of the latest transaction made, Baillie Gifford & CO holds 5,061,011 shares of GH stock, worth $231 Million. This represents 0.19% of its overall portfolio holdings.
Number of Shares
5,061,011
Previous 5,449,100
7.12%
Holding current value
$231 Million
Previous $166 Million
29.51%
% of portfolio
0.19%
Previous 0.13%
Shares
6 transactions
Others Institutions Holding GH
# of Institutions
392Shares Held
121MCall Options Held
1.43MPut Options Held
2.37M-
Vanguard Group Inc Valley Forge, PA12.1MShares$551 Million0.01% of portfolio
-
Black Rock Inc. New York, NY11.2MShares$513 Million0.01% of portfolio
-
Deep Track Capital, LP Greenwich, CT5.44MShares$248 Million8.11% of portfolio
-
Capital International Investors Los Angeles, CA5.15MShares$235 Million0.04% of portfolio
-
Cadian Capital Management, LP New York, NY4.6MShares$210 Million8.38% of portfolio
About Guardant Health, Inc.
- Ticker GH
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 102,220,000
- Market Cap $4.67B
- Description
- Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a cl...